Abstracts tagged "registry and rheumatoid arthritis (RA)"

Abstract Number: 478 • 2015 ACR/ARHP Annual Meeting
Impact of Comorbidities on the Multi-Biomarker Disease Activity Test in Rheumatoid Arthritis Patients
Jeffrey R. Curtis¹, Jeffrey D. Greenberg², Leslie Harrold³ and J. Lynn Palmer⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Corrona, LLC, Southborough, MA, ³Department of Medicine, UMass Memorial Medical Center, Worcester, MA, ⁴Corrona Research Foundation, Albany, NY
Background/Purpose: The multi-biomarker disease activity (MBDA) score [Vectra] has been evaluated in a number of settings, yet has only limited data evaluating whether it is…
Abstract Number: 459 • 2015 ACR/ARHP Annual Meeting
The Effect of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Positivity on Drug Survival of Abatacept in Patients with Rheumatoid Arthritis in Routine Care: The Results from Turkbio Registry
Ihsan Ertenli¹, Omer Karadag¹, Yavuz Pehlivan², Ediz Dalkilic³, Ahmet Mesut Onat⁴, Bunyamin Kisacik⁵, Gercek Can⁶, Servet Akar⁷, Sedat Capar⁸, Umut Kalyoncu¹, Mustafa Ferhat Oksuz⁹, Emine Figen Tarhan⁷ and Nurullah Akkoc⁶, ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Department of Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ³Department of Rhematology, Uludag University Faculty of Medicine, Bursa, Turkey, ⁴Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁵Rheumatology Department, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁶Department of Rheumatology, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey, ⁷Department of Internal Medicine, Division of Rheumatology, Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁸Dokuz Eylül University Faculty of Statistics, Izmir, Turkey, ⁹Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey
Background/Purpose: Abatacept (ABA) is a biological anti-rheumatic drug used in Rheumatoid Arthritis (RA). In TURKBIO, Turkish Biologic Registry, data on patient characteristics, diagnosis, previous treatment…
Abstract Number: 455 • 2015 ACR/ARHP Annual Meeting
Predictors of Real-World Treatment Sustainability in RA Patients Treated with Abatacept in Canada: Implications for Routine Care
Janet E. Pope¹, Emmanouil Rampakakis² and John S. Sampalis³, ¹University of Western Ontario, London, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³Clinical Research, JSS Medical Research, Westmount, QC, Canada
Background/Purpose: Treatment sustainability can measure drug effectiveness and encompasses drug effectiveness, safety, and compliance. Recent data suggest that differences in retention may exist between biologic…
Abstract Number: 2669 • 2015 ACR/ARHP Annual Meeting
Persistency of Patient Reported Morning (AM) Stiffness in a Large US Registry Cohort of Rheumatoid Arthritis (RA) Patients Initiating New DMARD Therapy
Vibeke Strand¹, Robert J. Holt², Heather J. Litman³, Jeffrey D. Kent⁴, Hristina Pashova⁵, John T. Nguyen³ and Carol J. Etzel^6,7, ¹Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, CA, ²University of Illinois - Chicago, Chicago, IL, ³Corrona, LLC., Southborough, MA, ⁴Horizon Pharma USA, Inc., Deerfield, IL, ⁵Axio Research, LLC., Seattle, WA, ⁶The University of Texas MD Anderson Cancer Center, Houston, TX, ⁷Corrona, LLC, Southborough, MA
Background/Purpose: AM stiffness is a common yet under-appreciated symptom in RA. The longitudinal impact of AM stiffness has not been previously investigated. This study evaluated…
Abstract Number: 1597 • 2015 ACR/ARHP Annual Meeting
Variability in Health Assessment Questionnaire Based on Type of Health Insurance Coverage and Rheumatology Practice
Jacqueline Stewart¹, Regan Arendse², Boulos Haraoui³, Michael Starr⁴, Denis Choquette⁵, Michelle Teo⁶, Dalton Sholter⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Brendan Osborne¹⁰, Karina Maslova¹¹, Cathy Tkaczyk¹⁰, Francois Nantel¹² and Allen J Lehman¹¹, ¹Penticton Regional Hospital, Penticton, BC, Canada, ²University of Saskatchewan, Saskatoon, SK, Canada, ³Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁴Rheumatology, McGill University, Montreal, QC, Canada, ⁵Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁶Rheumatology, Penticton Regional Hospital, Penticton, BC, Canada, ⁷Rheumatology Associates, Edmonton, AB, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose : Previous studies in rheumatoid arthritis (RA) have shown that patient socioeconomic status (SES) impacts patient prognosis. We hypothesized that public vs. private healthcare…
Abstract Number: 1437 • 2015 ACR/ARHP Annual Meeting
Prevalence of Pain, Its Impact and Management in a Population-Based Cohort of Patients with Rheumatoid Arthritis: Data from the Australian Rheumatology Association Database
Bethan Richards^1,2, Rachelle Buchbinder³, Marissa N. Lassere⁴ and Lyn March⁵, ¹Sydney Medical School, University of Sydney, Sydney, Australia, ²Royal Prince Alfred Hospital, Mulgrave, Vic, Australia, ³Monash Department of Clinical Epidemiology, Cabrini Institute and Monash University, Melbourne, Australia, ⁴Dept of Rheumatology, St George Hospital, Kogarah, Australia, ⁵Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia
Background/Purpose: Despite advances in the treatments available for rheumatoid arthritis (RA), many patients continue to experience musculoskeletal pain. Untreated and under-treated pain are well known to increase…
Abstract Number: 599 • 2015 ACR/ARHP Annual Meeting
An Examination of Dose Escalation Among Remicade (infliximab) Users in a US RA Registry
Jeffrey R. Curtis¹, Ying Shan², Joel M. Kremer³, Katherine Saunders⁴, Dennis Parenti⁵ and Shelly Kafka⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²UMass Memorial Medical Center, Worcester, MA, ³Albany Medical College, Albany, NY, ⁴Corrona LLC, Atlanta, GA, ⁵Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: Limited data are available about infliximab(IFX) dose escalation. This analysis examines the frequency of dose escalation among IFX patients using data from the US…
Abstract Number: 497 • 2015 ACR/ARHP Annual Meeting
Treatment Outcomes in Elderly Patients with Rheumatoid Arthritis: Results from a Nationwide Korean Biologics Registry
Seung Min Jung¹, Ji Yeon Lee¹, Jung Hee Koh¹, Seung-Ki Kwok², Ji Hyeon Ju¹, Chong-Hyeon Yoon¹ and Sung-Hwan Park¹, ¹Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ²seungki73@catholic.ac.kr, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease, predominantly affecting women in their fifth and sixth decades of life. Although population aging increases the…
Abstract Number: 488 • 2015 ACR/ARHP Annual Meeting
Six-Year Retention Rates with Abatacept Vs TNF Inhibitors in the Treatment of Rheumatoid Arthritis: Experience from the Real-World Rhumadata Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Boulos Haraoui³, Jean-Pierre Raynauld¹, Diane Sauvageau¹, Angèle Turcotte⁴, Édith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Université de Montréal, Montreal, QC, Canada, ⁴Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada
Background/Purpose: The sustainability of any regimen is an important factor to consider when selecting therapy for chronic conditions, such as rheumatoid arthritis (RA). Recent reports…
Abstract Number: 2813 • 2014 ACR/ARHP Annual Meeting
Correlation of Morning Stiffness with Measures of Higher Disease Activity in a Large US Registry Population of Rheumatoid Arthritis Patients
Vibeke Strand¹, Robert J. Holt², Katherine C. Saunders³, Jeffery D. Kent⁴, Ping Xu⁵, Amy Y. Grahn⁴, Marc Mason³ and Carol J. Etzel^6,7, ¹Stanford University, Palo Alto, CA, ²University of Illinois - Chicago, Chicago, IL, ³Corrona, LLC., Southborough, MA, ⁴Horizon Pharma, Inc., Deerfield, IL, ⁵Axio Research LLC, Seattle, WA, ⁶PO Box 786, Corrona, LLC., Southborough, MA, ⁷Department of Epidemiology, UT MD Anderson, Houston, TX
Background/Purpose : Morning stiffness may not be specifically queried by rheumatologists in the course of their regular interactions with rheumatoid arthritis (RA) patients. This analysis…
Abstract Number: 2562 • 2014 ACR/ARHP Annual Meeting
The Comparative One-Year Drug Survival Rate of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid arthritis and ankylosing spondylitis; results from Turkbio Registry
Ismail Sari¹, Umut Kalyoncu², Ahmet Mesut Onat³, Omer Nuri Pamuk⁴, Omer Karadag², Bunyamin Kisacik³, Niels Steen Krogh⁵, Soner Şenel⁶, Fatih Saritaş⁷, Ihsan Ertenli², Sedat Kiraz², Pinar Cetin¹, Fatos Onen¹ and Nurullah Akkoc¹, ¹Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ²Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey, ³Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁴Department of Rheumatology, Trakya University School of Medicine, Edirne, Turkey, ⁵Consultant, ZiteLab Aps, Copenhagen, Denmark, ⁶Rheumatology, Erciyes University School of Medicine, Kayseri, Turkey, ⁷Rheumatology, Trakya University School of Medicine, Edirne, Turkey
Background/Purpose Three different anti–tumor necrosis factor α (anti-TNFα) drugs (infliximab, etanercept, and adalimumab) are approved for patients with rheumatoid arthritis (RA) and particular ankylosing spondylitis…
Abstract Number: 2504 • 2014 ACR/ARHP Annual Meeting
Impact of Concomitant Methotrexate on the Enhanced Clinical Efficacy of Abatacept after 24 Weeks in Rheumatoid Arthritis Patients
Nobunori Takahashi¹, Toshihisa Kojima¹, Yuji Hirano², Yasuhide Kanayama³, Koji Funahashi⁴ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ³Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose Abatacept (ABT), a selective co-stimulation modulator, is the first in a new class of biologic agents for the treatment of rheumatoid arthritis (RA) that…
Abstract Number: 2416 • 2014 ACR/ARHP Annual Meeting
Do Patterns of Joint Swelling or Tenderness in Rheumatoid Arthritis Patients Impact Disease Activity Outcomes and Pain? Implications for Clinical Practice
Regan Arendse¹, John Kelsall², J. Antonio Avina-Zubieta³, Philip Baer⁴, Erica Weinberg⁴, Jude Rodrigues⁵, Algis Jovaisas⁶, Isabelle Fortin⁷, Maqbool Sheriff⁸, Majed M. Khraishi⁹, Emmanouil Rampakakis¹⁰, John S. Sampalis¹⁰, Francois Nantel¹¹, Susan Otawa¹² and Allen J Lehman¹², ¹University of Saskatchewan, Saskatoon, SK, Canada, ²The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Private Practice, Scarborough, ON, Canada, ⁵Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁶194 Main Street, University of Ottawa, Ottawa, ON, Canada, ⁷Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁸Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁹Nexus Clinical Research, Memorial University of Newfoundland, St Johns, NF, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose This analysis aimed to describe the pattern of specific joint involvement (tender and/or swollen) pre- and post-TNFi treatment and the impact of specific joint…
Abstract Number: 1537 • 2014 ACR/ARHP Annual Meeting
Clinical Characteristics of RA Patients Newly Prescribed Tofacitinib Citrate (tofacitinib) in the United States after Food and Drug Administration Approval: Results from the Corrona US Rheumatoid Arthritis Registry
Arthur Kavanaugh¹, George W. Reed^2,3, Katherine C. Saunders², Andrew S. Koenig⁴, Jamie Geier⁵, Joel M. Kremer⁶, Jeffrey D. Greenberg^2,7 and Clifton O. Bingham III⁸, ¹University of California San Diego, La Jolla, CA, ²Corrona, LLC., Southborough, MA, ³University of Massachusetts Medical School, Worcester, MA, ⁴Pfizer, Inc., Collegeville, PA, ⁵Pfizer, Inc., New York, NY, ⁶Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁷Rheumatology, New York University School of Medicine, New York, NY, ⁸Johns Hopkins University, Baltimore, MD
Background/Purpose: To provide initial characterization of the patients prescribed tofacitinib during the early period after United States (US) Food and Drug Administration (FDA) approval (11/6/2012).…
Abstract Number: 1397 • 2014 ACR/ARHP Annual Meeting
Impact of Corticosteroid Use on Remission Sustainability and Infection Rates Among Rheumatoid Arthritis Patients in Remission While on Infliximab: Treatment Implications Based on a Real-World Canadian Population
Boulos Haraoui¹, Algis Jovaisas², William G. Bensen³, Rafat Faraawi⁴, John Kelsall⁵, Sanjay Dixit⁴, Jude Rodrigues⁶, Maqbool Sheriff⁷, Emmanouil Rampakakis⁸, John S. Sampalis⁸, Allen J Lehman⁹, Susan Otawa⁹, Francois Nantel¹⁰ and May Shawi¹⁰, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Department of Medicine, Division of Rheumatology, St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁶Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada
Background/Purpose The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…